ClinicalTrials.gg
Active, not recruitingNCT04023370Updated Oct 26, 2024

Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System

An interventional study of Treatment of primary iliac artery stenosis and/or occlusive lesions in Iliac Artery Stenosis, sponsored by Bentley InnoMed GmbH. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Bentley InnoMed GmbH · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The trial will be conducted to evaluate the safety and efficacy of the BeGraft Peripheral Stent Graft System in interventional revascularisation for subjects with primary iliac artery stenosis and/or occlusive lesions by conducting a multi-centre, randomised controlled clinical study with a bare metal stent system as the control, thus providing a basis for the formal use of the product in China

Read the detailed description

This study adopts a prospective, multi-centre, randomised controlled trial design, aiming at evaluating the efficacy and safety of the BeGraft Peripheral Stent Graft System for primary iliac artery stenosis and/or occlusive lesions. A total of 182 subjects are planned to be enrolled, with all consecutively enrolled subjects being randomly assigned to an experimental group (BeGraft group, n=91) and a control group (bare metal stent group, n=91) in the ratio of 1:1 and respectively treated using the BeGraft Peripheral Stent Graft System and the bare metal stent system. Follow-up visits are carried out for the above-mentioned 182 subjects at baseline, upon discharge from hospital, at 30 days, 6 months, 12 months and then once a year from the 2nd to 5th year following surgery. A Doppler ultrasound (DUS) examination is carried out when subjects return to hospital at 6 months following surgery, and a CT angiography (CTA) examination when returning 12 months following surgery, with telephone follow-ups being conducted at 30 days and then once a year from the 2nd to 5th year following surgery.

02

Conditions studied

  • Iliac Artery Stenosis
03

In context

Constriction, Pathologic

456 studies on the registry are indexed under Constriction, Pathologic; 109 are open to participants now.

This study's planned enrollment of 182 is above the median of 72 across 295 interventional studies indexed under Constriction, Pathologic.

Browse Constriction, Pathologic studies →

Lead sponsor

Bentley InnoMed GmbH is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years old, no restrictions in terms of male or female;
  • Participating in the trial voluntarily, and having signed the form;
  • TASC class A, B, C or D lesions of the common iliac artery and/or external iliac artery;
  • Primary iliac atherosclerotic stenosis and/or occlusive lesions;
  • Total length of lesions on the affected side ≤100 mm.

Exclusion criteria

Exclusion Criteria:

  • Expected survival period \<12 months;
  • Pregnant women or those unable to take effective measures during the trial;
  • Aneurysms present close to the target lesion;
  • Acute or subacute thrombosis within the target vessel;
  • Previously unobstructed internal iliac artery being blocked (diameter stenosis \<70%) by the stented region;
  • Total occlusive lesions, with the guidewire being unable to return the true lumen in the iliac artery;
  • Severe calcification at the target lesion, with the catheter being unable to pass;
  • Allergic to cobalt-chromium alloy (L605), ePFTE coating material, carbon coating, contrast agent, antiplatelet agents, anticoagulant drugs or presenting with ;
  • Total occlusion of the superficial femoral artery and deep femoral artery, with there being no outflow tract;
  • Suffering from extensive diffuse disease at the distal end, resulting in poor blood flow in the outflow tract following stent placement;
  • A history of coagulation disorders;
  • The subject's mental state making it impossible for them to comprehend the nature, extent and possible consequences of the trial, or having a language barrier making it difficult for the subject to give their ;
  • Poor cooperation or potentially poor compliance with the protocol which may cause deviations during the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    BeGraft Peripheral Stent Graft System

    Covered stent

    Device: Treatment of primary iliac artery stenosis and/or occlusive lesions

  • Active comparator
    Bare metal stent system

    bare metal stent

    Device: Treatment of primary iliac artery stenosis and/or occlusive lesions

Interventions

  • DeviceTreatment of primary iliac artery stenosis and/or occlusive lesions

    Stent implantation

06

What researchers measure

Primary outcomes

  1. Primary patency rate

    The primary patency rate is defined as the absence of restenosis in the treated vessel segment without accompanying target lesion revascularisation (TLR) or amputation.

    Time frame: 12 month

Secondary outcomes

  1. Device/Surgical success rate

    Stent placement and integrity

    Time frame: 30 days, 6 months and 12 months following surgery, and then once a year from the 2nd to 5th year following surgery

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04023370
Lead sponsor
Bentley InnoMed GmbH
Collaborators
Shanghai Micro Medical Devices Co., Ltd.
Responsible party
Sponsor
First posted
Jul 17, 2019
Start date
Sep 19, 2019
Primary completion
Sep 30, 2022
Completion
Aug 31, 2025 (estimated)
Last update
Oct 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion